Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2012

Global Markets Direct, November 2012, Pages: 45

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS). Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cognitive Impairment Associated With Schizophrenia (CIAS).
- A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) 7
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics under Development by Companies 9
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics – Products under Development by Companies 14
Companies Involved in Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Development 15
Abbott Laboratories 15
Amgen Inc. 16
Eli Lilly and Company 17
Takeda Pharmaceutical Company Limited 18
Avineuro Pharmaceuticals, Inc. 19
PsychoGenics, Inc. 20
Galenea Corp. 21
Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AMG-747 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AVN-211 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
eltoprazine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ABT-126 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ABT-288 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
5-HT6 Antagonist Program - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AMG-579 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MGluR5 PAM - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drug For Cognitive Impairment - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ITI-214 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics – Drug Profile Updates 39
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics – Discontinued Products 42
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Dormant Products 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products Under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2012 7
Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Abbott Laboratories, H2 2012 15
Amgen Inc., H2 2012 16
Eli Lilly and Company, H2 2012 17
Takeda Pharmaceutical Company Limited, H2 2012 18
Avineuro Pharmaceuticals, Inc., H2 2012 19
PsychoGenics, Inc., H2 2012 20
Galenea Corp., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics – Drug Profile Updates 39
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics – Discontinued Products 42
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics – Dormant Products 43

List of Figures
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2012 7
Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Customers who bought this item also bought

• Cognitive Impairment - Pipeline Review, H2 2012
• Schizophrenia - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Movement Disorders - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Epilepsy - Pipeline Review, H2 2012